// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

In acpa positive at-risk individuals, which mri and us findings best predict development of clinical synovitis?

L. Hunt - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

In ra patients with initial response to rituximab, early depth of b cell depletion is associated with long term maintenance of therapy

L Garcia Montoya - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Rituximab

In sle patients in sustained low disease activity, novel interferon assays predict flares and glucocorticoid requirements

K. Dutton - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Glucocorticoid

Increasing incidence of adult idiopathic inflammatory myopathies: a ten-year uk epidemiological study

M.J.S. Parker - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic inflammatory myopathies

N/A

Inertial motion sensors using the vimove© system is a valid method to assess spinal mobility in patients with axial spondyloarthritis

I.C. Aranda-Valera - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

Inflammation and cancer: friend or foe

C.S. Roxburgh - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Inflammation-induced formation of fat associated lymphoid clusters

J. Caamano - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Inflammatory or rheumatoid arthritis patients’ perspectives on the effect of arthritis gloves on their hand pain and function (A-GLOVES TRIAL: a qualitative study

Y Prior - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

Influence of epidemiology and ethnicity on systemic expression of primary sjÖgren syndrome in 9974 patients

S Retamozo - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

N/A

Initial development of a whole-body magnetic resonance imaging inflammation index for active disease of peripheral joints and entheses in patients with inflammatory arthritis

S. Krabbe - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Integrated safety data analysis across phase 3 clinical studies for intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis

M.E. Husni - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

golimumab

Intense aerobic and resistance exercise reduces the frequency of peripheral blood regulatory cell populations in elderly patients with rheumatoid arthritis

S. Andersson - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

N/A

International league of associations for rheumatology (ILAR treatment recommendations for psoriatic arthritis in resource-poor countries

M. Elmamoun - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriatic arthritis

N/A

Interventions for morphea: a cochrane systematic review

J.V. de Albuquerque - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Investigating the regulatory snps at the runx3 locus associated with ankylosing spondylitis

M.L. Vecellio - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ankylosing spondylitis

N/A

Is dose banding of infliximab cost effective – results from real world implementation

M.K. Nisar - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Infliximab

Is lupus more prevalent in world’s most stressed countries?

A. Almathkouri - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

Is the icoap a valid tool for measuring pain and function in patients with knee oa and ra in clinical practice?

J. Obire - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Ixekizumab treatment significantly improves enthesitis and dactylitis in patients with active psoriatic arthritis: results from the spirit trials

D.D. Gladman - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Psoriatic arthritis

LY2439821

Juvenile inflammatory arthritis: the development and validation of an illustrated questionnaire to measure children’s motivation

Y. El Miedany - European League Against Rheumatism (EULAR) , 2018

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

N/A

Copyright © 2026. QuantiNova All rights reserved